免疫评分在III期结直肠癌中的预后和预测价值:SCOT与IDEA-HORG研究病例的汇总分析
该汇总分析纳入SCOT和IDEA-HORG试验中2643例适合免疫评分检测的III期结直肠癌病例,评估免疫评分对接受FOLFOX或CAPOX辅助化疗患者的预后和预测价值。结果显示免疫评分低与无病生存期显著缩短相关(合并队列mvHR 1.55,95%CI 1.34-1.79,P<.001),且将免疫评分加入临床变量模型可显著改善无病生存期预测(似然比检验P<.001)。免疫评分预后价值随年龄和错配修复状态可能的差异,以及其对延长辅助治疗获益的预测作用,尚需验证。
要点
- 在SCOT和IDEA-HORG试验的2608例可评估III期结直肠癌中,877例(33.7%)为免疫评分低。
- 免疫评分低者无病生存期显著缩短:CAPOX队列mvHR 1.52,FOLFOX队列mvHR 1.58,合并队列mvHR 1.55(均P<.001)。
- 免疫评分加入含全部临床变量的模型可显著改善无病生存期预测(似然比检验P<.001),无论错配修复状态如何。
核心结论
- 免疫评分在接受FOLFOX或CAPOX治疗的III期结直肠癌中具有预后价值,包括在临床相关肿瘤亚组内。
- 免疫评分预后价值随年龄和错配修复状态可能的差异,以及其对延长辅助治疗获益的预测作用,尚需验证。
研究设计与样本
- SCOT和IDEA-HORG试验病例的汇总分析。
- 采用预设截断值(免疫评分低和免疫评分高)将病例分为两组,通过Cox回归分析3年无病生存期和多变量校正风险比(mvHR)。
主要发现
- 2608例(99.5%)可评估病例中确定了免疫评分,877例(33.7%)样本分类为免疫评分低。
- 免疫评分低肿瘤更常见于高风险(T4和/或N2;免疫评分低52.9% vs 免疫评分高42.2%;P<.001)和年轻患者(P=.024)。
- 免疫评分低患者无病生存期显著缩短:CAPOX队列mvHR 1.52(95%CI 1.28-1.82),FOLFOX队列mvHR 1.58(95%CI 1.22-2.04),合并队列mvHR 1.55(95%CI 1.34-1.79),所有比较P<.001;且不受性别、BMI、临床风险组、肿瘤部位、治疗时长或化疗方案影响。
- CAPOX队列中,免疫评分预后价值在年轻(≤65岁)患者大于老年(>65岁)患者(mvHR 1.92 [95%CI 1.50-2.46] vs 1.28 [95%CI 1.01-1.63],P交互=.026);在错配修复 proficient 大于错配修复 deficient 疾病中(mvHR 1.68 [95%CI 1.41-2.00] vs 0.67 [95%CI 0.30-1.49],P交互=.03),但这些探索性分析未校正多重检验。
- 将免疫评分加入含全部临床变量的模型可显著改善无病生存期预测(似然比检验P<.001),无论错配修复状态如何。
临床怎么用
- 原文未据此给出推荐。
局限性
- 免疫评分预后价值随年龄和错配修复状态可能的差异,以及其对延长辅助治疗获益的预测作用,尚需验证。
- 这些探索性分析未校正多重检验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunoscore (IS) is prognostic in stage III colorectal cancer (CRC) and may predict benefit of duration (6 v 3 months) of adjuvant infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy. We sought to determine IS prognostic and predictive value in stage-III CRC treated with adjuvant FOLFOX or oral capecitabine and infusional oxaliplatin (CAPOX) in the SCOT and IDEA-HORG trials. METHODS: Three thousand sixty-one cases had tumor samples, of which 2,643 (1,792 CAPOX) were eligible for IS testing. Predefined cutoffs (IS-Low and IS-High) were used to classify cases into two groups for analysis of disease-free survival (3-year DFS) and multivariable-adjusted hazard ratios (mvHRs) by Cox regression. RESULTS: IS was determined in 2,608 (99.5%) eligible cases, with 877 (33.7%) samples classified as IS-Low. IS-Low tumors were more commonly high-risk (T4 and/or N2; 52.9% IS-Low v 42.2% IS-High; P < .001) and in younger patients (P = .024). Patients with IS-Low tumors had significantly shorter DFS in the CAPOX, FOLFOX, and combined cohorts (mvHR, 1.52 [95% CI, 1.28 to 1.82]; mvHR, 1.58 [95% CI, 1.22 to 2.04]; and mvHR, 1.55 [95% CI, 1.34 to 1.79], respectively; P < .001 all comparisons), regardless of sex, BMI, clinical risk group, tumor location, treatment duration, or chemotherapy regimen. IS prognostic value was greater in younger (≤65 years) than older (>65 years) patients in the CAPOX cohort (mvHR, 1.92 [95% CI, 1.50 to 2.46] v 1.28 [95% CI, 1.01 to 1.63], PINTERACTION = .026), and in DNA mismatch repair proficient than deficient mismatch repair disease (mvHR, 1.68 [95% CI, 1.41 to 2.00] v 0.67 [95% CI, 0.30 to 1.49], PINTERACTION = .03), although these exploratory analyses were uncorrected for multiple testing. Adding IS to a model containing all clinical variables significantly improved prediction of DFS (likelihood ratio test, P < .001) regardless of MMR status. CONCLUSION: IS is prognostic in stage III CRC treated with FOLFOX or CAPOX, including within clinically relevant tumor subgroups. Possible variation in IS prognostic value by age and MMR status, and prediction of benefit from extended adjuvant therapy merit validation.
引用
- Domingo E, Kelly C, Hay J, et al. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies. J Clin Oncol. 2024. PMID: 38484206. doi:10.1200/JCO.23.01648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。